Invasive Breast Carcinoma

About
Mappings

OncoTree: Invasive Breast Carcinoma (oncotree:BRCA)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this cancer type.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Tamoxifen FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Tamoxifen FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Tamoxifen FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Anastrozole FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Anastrozole FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Anastrozole FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Letrozole FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Letrozole FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Letrozole FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Exemestane FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Anastrozole FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Anastrozole FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Anastrozole FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Letrozole FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Letrozole FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Letrozole FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Fulvestrant FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Trastuzumab emtansine FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Trastuzumab emtansine FDA
Sensitivity (+) ER positive, HER2-negative, PIK3CA somatic variants Invasive Breast Carcinoma Alpelisib, Fulvestrant FDA
Sensitivity (+) HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Alpelisib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Alpelisib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PIK3CA somatic variants Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) AKT1 somatic variants, ER positive, HER2-negative Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) AKT1 somatic variants, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) AKT1 somatic variants, ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) AKT1 amplification, ER positive, HER2-negative Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) AKT1 amplification, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) AKT1 amplification, ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) HER2-negative, PR positive, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PR positive, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) HER2-negative, PR positive, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PR positive, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) HER2-negative, PR positive, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PR positive, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) HER2-negative, PR positive, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PR positive, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) ER positive, ESR1 oncogenic variants, HER2-negative Invasive Breast Carcinoma Elacestrant FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Everolimus, Exemestane FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant FDA
Sensitivity (+) ER positive Invasive Breast Carcinoma Fulvestrant FDA
Sensitivity (+) PR positive Invasive Breast Carcinoma Fulvestrant FDA
Sensitivity (+) ER positive, PR positive Invasive Breast Carcinoma Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant, Ribociclib FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Ribociclib FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Ribociclib FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Fulvestrant FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant, Palbociclib FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Capecitabine, Lapatinib FDA
Sensitivity (+) ER positive, HER2-positive Invasive Breast Carcinoma Lapatinib, Letrozole FDA
Sensitivity (+) HER2-positive, PR positive Invasive Breast Carcinoma Lapatinib, Letrozole FDA
Sensitivity (+) ER positive, HER2-positive, PR positive Invasive Breast Carcinoma Lapatinib, Letrozole FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Capecitabine, Margetuximab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Eribulin, Margetuximab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Gemcitabine, Margetuximab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Margetuximab, Vinorelbine FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Neratinib FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Capecitabine, Neratinib FDA
Sensitivity (+) BRCA1 pathogenic variants, HER2-negative Invasive Breast Carcinoma Olaparib FDA
Sensitivity (+) BRCA2 pathogenic variants, HER2-negative Invasive Breast Carcinoma Olaparib FDA
Sensitivity (+) BRCA1 pathogenic variants, HER2-negative Invasive Breast Carcinoma Olaparib FDA
Sensitivity (+) BRCA2 pathogenic variants, HER2-negative Invasive Breast Carcinoma Olaparib FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Letrozole, Palbociclib FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant, Palbociclib FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib FDA
Sensitivity (+) ER negative, HER2-negative, PR negative Invasive Breast Carcinoma Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Pembrolizumab FDA
Sensitivity (+) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Paclitaxel, Pembrolizumab FDA
Sensitivity (+) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Carboplatin, Gemcitabine, Pembrolizumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Docetaxel, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Carboplatin, Docetaxel, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Carboplatin, Docetaxel, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Docetaxel, Pertuzumab, Trastuzumab FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Anastrozole, Ribociclib FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Ribociclib FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Ribociclib FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Letrozole, Ribociclib FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Ribociclib FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Ribociclib FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant, Ribociclib FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Ribociclib FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Ribociclib FDA
Sensitivity (+) ER negative, HER2-negative, PR negative Invasive Breast Carcinoma Sacituzumab govitecan FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Sacituzumab govitecan FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Sacituzumab govitecan FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Sacituzumab govitecan FDA
Sensitivity (+) BRCA1 pathogenic variants, HER2-negative Invasive Breast Carcinoma Talazoparib FDA
Sensitivity (+) BRCA2 pathogenic variants, HER2-negative Invasive Breast Carcinoma Talazoparib FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Trastuzumab deruxtecan FDA
Sensitivity (+) HER2-low Invasive Breast Carcinoma Trastuzumab deruxtecan FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Pertuzumab, Trastuzumab deruxtecan FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Capecitabine, Trastuzumab, Tucatinib FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib FDA
Sensitivity (+) ER positive, HER2-negative, PIK3CA somatic variants Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib FDA
Sensitivity (+) HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib FDA
Sensitivity (+) ER positive, HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib FDA
Sensitivity (+) EGFR Exon 20 (Insertion) Invasive Breast Carcinoma Datopotamab deruxtecan FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Datopotamab deruxtecan FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Datopotamab deruxtecan FDA
Sensitivity (+) ER positive, ESR1 oncogenic variants, HER2-negative Invasive Breast Carcinoma Imlunestrant FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Everolimus, Exemestane HC
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane HC
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Trastuzumab deruxtecan HC
Sensitivity (+) HER2-low Invasive Breast Carcinoma Trastuzumab deruxtecan HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Trastuzumab deruxtecan HC
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Docetaxel, Paclitaxel, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Carboplatin, Docetaxel, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Docetaxel, Pertuzumab, Trastuzumab HC
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Letrozole, Palbociclib HC
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib HC
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib HC
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant, Palbociclib HC
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib HC
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib HC
Sensitivity (+) ER positive, HER2-negative, PIK3CA somatic variants Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib HC
Sensitivity (+) HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib HC
Sensitivity (+) ER positive, HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Trastuzumab emtansine HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Trastuzumab emtansine HC
Sensitivity (+) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Paclitaxel, Pembrolizumab HC
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Anastrozole, Ribociclib HC
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Ribociclib HC
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Ribociclib HC
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Letrozole, Ribociclib HC
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Ribociclib HC
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Ribociclib HC
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant, Ribociclib HC
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Ribociclib HC
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Ribociclib HC
Sensitivity (+) BRCA1 pathogenic variants, HER2-negative Invasive Breast Carcinoma Olaparib HC
Sensitivity (+) BRCA2 pathogenic variants, HER2-negative Invasive Breast Carcinoma Olaparib HC
Sensitivity (+) BRCA1 pathogenic variants, HER2-negative Invasive Breast Carcinoma Olaparib HC
Sensitivity (+) BRCA2 pathogenic variants, HER2-negative Invasive Breast Carcinoma Olaparib HC
Sensitivity (+) ER positive, HER2-positive, PR positive Invasive Breast Carcinoma Neratinib HC
Sensitivity (+) ER positive, HER2-positive Invasive Breast Carcinoma Neratinib HC
Sensitivity (+) HER2-positive, PR positive Invasive Breast Carcinoma Neratinib HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Capecitabine, Neratinib HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Docetaxel, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Carboplatin, Docetaxel, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Carboplatin, Paclitaxel, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Paclitaxel, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Pertuzumab, Trastuzumab, Vinorelbine HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Docetaxel, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Docetaxel, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Carboplatin, Docetaxel, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Carboplatin, Paclitaxel, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Paclitaxel, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Pertuzumab, Trastuzumab, Vinorelbine HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Docetaxel, Pertuzumab, Trastuzumab HC
Sensitivity (+) ER negative, HER2-negative, PD-L1 >= 1%, PR negative Invasive Breast Carcinoma Atezolizumab, Nab-paclitaxel HC
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Sacituzumab govitecan HC
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Sacituzumab govitecan HC
Sensitivity (+) HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) ER positive, HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) AKT1 somatic variants, ER positive, HER2-negative Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) AKT1 somatic variants, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) AKT1 somatic variants, ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) AKT1 amplification, ER positive, HER2-negative Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) AKT1 amplification, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) AKT1 amplification, ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) ER positive, HER2-negative, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) HER2-negative, PR positive, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) ER positive, HER2-negative, PR positive, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) ER positive, HER2-negative, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) HER2-negative, PR positive, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) ER positive, HER2-negative, PR positive, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) ER positive, HER2-negative, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) HER2-negative, PR positive, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) ER positive, HER2-negative, PR positive, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) ER positive, HER2-negative, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) HER2-negative, PR positive, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) ER positive, HER2-negative, PR positive, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) ER positive, HER2-negative, PIK3CA amplification Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Capecitabine, Trastuzumab, Tucatinib HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Capecitabine, Lapatinib HC
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Tamoxifen HC
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Tamoxifen HC
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Tamoxifen HC
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib HC
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib HC
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib HC
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane HC
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Exemestane HC
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane HC